Hicharm Bio Leverages Hong Kong's Strategic Hub to Accelerate Global Innovative Drug Layout
Haichang Biotech
Innovative Formulation Developer
Click the blue words above to follow us
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
As a key move in Haichang Biotech's globalization strategy,Hong Kong White Oak Pharmaceuticals Co., Ltd.(Haichang Biotech's wholly-owned subsidiary) has successfully gained approval to proceed, leveraging its international R&D system and cutting-edge technology platform.“Phase II Clinical Study of HC0301 Combined with Sorafenib for Second-Line Treatment of Advanced Hepatocellular Carcinoma Patients”。The drug is based on QTsome, which was independently developed by Haichang Biotech and has global intellectual property rights.®Delivery Technology: By efficiently encapsulating the antisense oligonucleotide Archexin within lipid nanoparticles, HC0301 achieves high-specificity inhibition of the AKT-1 signaling pathway. Given AKT-1's central regulatory role in the proliferation, drug resistance, and angiogenesis of solid tumors such as hepatocellular carcinoma, HC0301 demonstrates breakthrough anti-tumor activity by precisely blocking the expression of this target protein, offering a novel therapeutic option for patients with advanced hepatocellular carcinoma.
Hong Kong White Oak MedicineThe rapid growth,Not only demonstrates Haichang Biotech's technical capabilities in overseas markets, but also showcases how it integrates resources and seizes trends.Opportunities, Assisting Mainland Pharmaceutical Companies to Establish in Hong Kong, Advancing on the Path to Globalization. ForumDuring, Haichang BiotechFounderDr. Zhao Xiaobin deeply analyzed the underlying logic of enterprises choosing Hong Kong as an internationalization window:"Hong Kong boasts the locational advantage of a super connector and the ability to allocate global capital. It can efficiently align with international clinical resources and regulatory standards, while relying on its mature capital market to support R&D innovation."By integrating the Chinese mainland and Hong KongTheIndustrial resources, Haichang Biotech has built a full value chain system from technology transfer to commercialization, for the biotechnology industry in China.PharmaceuticalsEnterprise"Going Global" Provides a Replicable Paradigm.
Looking ahead, Haichang Biotech will continue to enhance QTsome.® technology platform's global competitiveness, leveraging Hong Kong's advantages as a free financial port, based in Hong Kong, radiating to the Asia-Pacific region, and connecting to global markets. Dr. Xiaobin Zhao said:"In the global competition for the value reconstruction of innovative drugs, Hong Kong is upgrading from a traditional financing platform to a strategic control point in the industrial value chain."Haichang Biotech will further deepen its synergy with Hong Kong's capital markets, accelerate the global layout of its innovative pipeline, and help China-produced original drugs define new value standards on the international stage.
About Haichang Biotech
Haichang Biotech, located in the China Medicine Port in Hangzhou, is a national-level specialized and innovative "little giant" enterprise that integrates research, production, and sales, with biopharmaceutical technology innovation as its core driving force. The company adheres to the core values of "sharing, progress, truth-seeking, and pragmatism," focusing on the technological development and industrial application of drug delivery systems. Its product pipeline covers multiple fields, including anti-cancer, cancer immunotherapy, pain relief, and infectious disease prevention.
Haichang Biotech's self-developed QTsome® technology platform has successfully broken through the international patent barriers of nucleic acid delivery systems, overcoming key "bottleneck" technologies. HC0301, a small nucleic acid innovative drug for primary liver cancer developed based on this platform, has entered Phase II of international multicenter clinical trials in China and the US, becoming one of the fastest progressing pipelines in the global field of precision small nucleic acid tumor treatment. In the high technical barrier and high value-added complex injectables sector, the company’s core product, albumin-bound paclitaxel for injection, has been approved for marketing in nearly 40 countries including China, the EU, and the UK. The company is the first domestic enterprise to obtain EU marketing authorization via centralized review, with two production sites simultaneously passing EU GMP inspections, leading the trend of high-end formulations "going overseas." HC016 lipid complex injection, the world's first TLR9 agonist based on lipid nanoparticle (LNP) delivery technology, has received IND approval from both China and the US. HC009, an mRNA COVID-19 vaccine booster, has obtained clinical approval from the US FDA, making it the first Chinese-produced mRNA vaccine product to receive US clinical authorization. Haichang Biotech has also received support from the "National Development and Reform Commission's Key Product Innovation and Application Demonstration Project for Biomanufacturing - First Batch of Projects in 2024," reflecting the company's technological accumulation and industrialization capabilities in the fields of small nucleic acid innovative drugs and complex formulations.